Preclinical assessment of β - d -mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug

Immunopharmacology and Immunotoxicology

Volumn 37, Issue 6, 2015, Pages 535-540

  Fattahi, Mohammad Javad ^a   Abdollahi, Mohammad ^b   Agha Mohammadi, Asghar ^c   Rastkari, Noushin ^b   Khorasani, Reza ^b   Ahmadi, Hossein ^a   Tofighi Zavareh, Farzaneh ^a   Sedaghat, Reza ^d   Tabrizian, Nakisa ^e   Mirshafiey, Abbas ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHED UNIVERSITY   (Iran)

^e UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Acute toxicity; M2000; non steroidal anti inflammatory drugs; subchronic toxicity; D mannuronic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CHOLESTEROL; CREATININE; GLUCOSE; MANNURONIC ACID; PHOSPHORUS; POTASSIUM; PROTEIN; SODIUM; TRIACYLGLYCEROL; URIC ACID; HEXURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPSY; BODY WEIGHT; CHROMATIN CONDENSATION; CONTROLLED STUDY; EOSINOPHIL; ERYTHROCYTE; HEMATOCRIT; HISTOPATHOLOGY; KIDNEY MASS; LIVER WEIGHT; LYMPHOCYTE COUNT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MONOCYTE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; STOMACH; UREA NITROGEN BLOOD LEVEL; ANIMAL; DOSE RESPONSE; PRECLINICAL STUDY; PROCEDURES; TOXICITY TESTING; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEXURONIC ACIDS; MALE; MICE; RATS; RATS, WISTAR; TOXICITY TESTS, ACUTE; TOXICITY TESTS, SUBCHRONIC;

EID: 84947754398     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2015.1113296     Document Type: Article

References (22)

1. Sidiropoulos P, Hatemi G, Song IH, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 2008; 47: 355-361
2. Reinhold S, Fischereder M, Riegger G, Krämer B. Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor. Clin Nephrol 2003; 60: 295-296
3. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008; 58: 929-938
4. Gaby AR. Alternative treatments for rheumatoid arthritis. Altern Med Rev 1999; 4: 392-402
5. Draget K, Smidsrød O, Skjåk-Bræk G. Alginates from algae. Biopolym Online 2005;6:215-240
6. Chhatbar M, Meena R, Prasad K, Siddhanta A. Microwave assisted rapid method for hydrolysis of sodium alginate for M/G ratio determination. Carbohydr Polym 2009; 76: 650-656
7. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012; 37: 106-126
8. Lanza RP, Kuhtreiber WM, Ecker DM, et al. Transplantation of porcine and bovine islets into mice without immunosuppression using uncoated alginate microspheres. Transplant Proc 1995; 27: 3321
9. Rehm BH. Alginate lyase from Pseudomonas aeruginosa CF1/M1 prefers the hexameric oligomannuronate as substrate. FEMS Microbiol Lett 1998; 165: 175-180
10. Mirshafiey A, Rehm B, Abhari RS, et al. Production of M2000(β- d -mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol 2007; 24: 60-66
11. Rehm BH, Valla S. Bacterial alginates: biosynthesis and applications. Appl Microbiol Biotechnol 1997; 48: 281-288
12. Mirshafiey A, Cuzzocrea S, Rehm B, et al. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand J Immunol 2005; 61: 435-441
13. Mirshafiey A, Cuzzocrea S, Rehm BH, Matsuo H. M2000: a revolution in pharmacology. Med Sci Monit 2005; 11: 153-163
14. Mirshafiey A, Matsuo H, Nakane S, et al. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol 2005; 27: 255-265
15. Mirshafiey A, Rehm B, Sotoude M, et al. Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immunotoxicol 2007; 29: 49-61
16. Hu J, Vanden Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-498
17. Mirshafiey A, Khorramizadeh MR, Saadat F, Rehm BH. Chemopreventive effect of M2000, a new anti-inflammatory agent. Med Sci Monit 2004; 10: 105-109
18. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-110
19. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949; 96: 99-113
20. Diallo A, Eklu-Gadegkeku K, Agbono A, et al. Acute and sub-chronic (28-day) oral toxicity studies of hydroalcohol leaf extract of Ageratum conyzoides L (Asteraceae). Trop J Pharm Res 2010; 9: 463-467
21. Mirghazanfari SM, Hosseinzadeh L, Shokoohinia Y, et al. Acute and subchronic toxicological evaluation of Echinophora platyloba DC (Apiaceae) total extract in Wistar rats. Clinics (Sao Paulo) 2012; 67: 497-502
22. Konate K, Bassole IH, Hilou A, et al. Toxicity assessment and analgesic activity investigation of aqueous acetone extracts of Sida acuta Burn f. and Sida cordifolia L. (Malvaceae), medicinal plants of Burkina Faso. BMC Complement Altern Med 2012; 12: 120